PainChek has expanded its Sabra relationship from two initial facilities to 23 US communities across five operators, covering 808 contracted memory care licences. The immediate test is whether those contracts become implemented recurring revenue by the end of 2026.
- 23 contracted communities across five US operators
- 808 memory care licences secured under Sabra expansion
- Implementation and licence activation targeted by 31 December 2026
- US assisted living and memory care opportunity estimated at 1.2 million licences
- A$100 million market estimate is not revenue guidance
Sabra footprint expands to 23 US communities
PainChek Limited (ASX:PCK) has moved from an initial two-site deployment to 23 contracted communities under its Sabra Health Care REIT relationship, a more tangible measure of US commercial traction than the headline market opportunity. The expansion covers five operators and 808 contracted memory care licences. It builds on the The next milestone is operational rather than contractual. PainChek is targeting implementation, staff training and licence activation across the 23 communities by 31 December 2026, with the stated aim of converting contracted uptake into implemented annual recurring revenue. The announcement does not disclose pricing, expected revenue from the 808 licences or the recurring revenue contribution once activated. The contracted sites span AgeWell, HDG, Phoenix Senior Living, The Claiborne and Traditions Senior Living. Together, those operators have 192 communities across their wider portfolios, although any expansion beyond the current contracts remains subject to further engagement and additional agreements. PainChek says its 808 contracted licences represent part of an initial memory care focus of roughly 2,500 licences within Sabra’s potential deployment opportunity of up to 20,000. Management is concentrating its near-term US sales effort on assisted living and memory care, estimating the segment at approximately 1.2 million potential licences and an addressable market of about A$100 million. Those figures are market estimates, not contracted demand or revenue forecasts. The company points to existing integrations, customer relationships and implementation experience in Australia and the UK as the basis for pursuing this segment before tackling broader opportunities in skilled nursing, hospitals and home care. A previously announced paid pilot with Silverado covers 203 licences across two sites, with the first site going live at the end of September 2026. Silverado operates 31 sites, which PainChek estimates could represent about 2,500 licences, but any expansion depends on the pilot’s evaluation and subsequent customer agreements. For now, the clearest indicator of progress will be whether PainChek can activate the Sabra licences on schedule and disclose what they contribute to recurring revenue. PainChek has secured a broader US commercial foothold, but the investment case now turns on activation, pricing and retention rather than licence potential alone.808 licences face an implementation test
Five operators provide room for further adoption
Assisted living and memory care become the US priority
Silverado pilot adds another conversion point
Bottom Line?
Questions in the middle?
Sources